Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NUVASIVE INCNUVA · Entity 110002 | President and COO | March 07, 2017 | March 09, 2017 |
| Orthofix Medical Inc.OFIX · Entity 1975 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NUVASIVE INC
Report date March 07, 2017 · Filed March 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,961 |
Last balance in matching sequence
After 2017-03-08 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2017-03-07 · Exercise / conversion · Acquired 97,375 · Balance 142,336 F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Row 2 · 2017-03-07 · Tax withholding · Disposed 72,535 · Balance 69,801 F2: Payment of exercise price and tax liability by Issuer's withholding of shares incident to the respective option exercise. F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Row 3 · 2017-03-08 · Sale · Disposed 24,340 · Balance 45,461 F3: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F4: Weighted average sales price from sales transactions ranging from $73.71 to $74.70. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Row 4 · 2017-03-08 · Sale · Disposed 500 · Balance 44,961 F3: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F5: Weighted average sales price from sales transactions ranging from $74.74 to $74.91. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.82 · Expires 2019-01-02 | Direct | 0 |
Reported balance
After 2017-03-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-07 · Exercise / conversion · Disposed 97,375 · Balance 0 F6: The option, representing a right to purchase a total of 97,375 shares, was granted on January 2, 2009 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards.
F2: Payment of exercise price and tax liability by Issuer's withholding of shares incident to the respective option exercise.
F3: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1.
F4: Weighted average sales price from sales transactions ranging from $73.71 to $74.70. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price.
F5: Weighted average sales price from sales transactions ranging from $74.74 to $74.91. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price.
F6: The option, representing a right to purchase a total of 97,375 shares, was granted on January 2, 2009 and is fully vested.
Orthofix Medical Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,662 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 14,965 · Balance 87,662 F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2: Includes 63,631 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
F2: Includes 63,631 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 22:29 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-269868 · ownership.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,662 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 63,631 previously reported deferred stock units and an aggregate of 2,103 shares acquired under Orthofix's Stock Purchase Plan ("Orthofix's SPP") on 10/31/2025 and 4/30/2026. Orthofix's SPP is a "Stock Purchase Plan" as defined in Rule 16b-3(b)(5), and share acquisitions under the plan are exempt from Section 16(b). Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:16 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 18,841 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088991 · ownership.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,594 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 44,790 previously reported deferred stock units and an aggregate of 2,389 shares acquired under Orthofix's Stock Purchase Plan on 10/31/2024 and 4/30/2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 11:06 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 15,152 | $12.87 | $195,006.24 |
DisclosureSEC source: 0000950170-24-075304 · ownership.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,364 F1 · shares: Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. F2 · balance_after: Includes 44,790 deferred stock units. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 00:00 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002650 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,285 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the first anniversary of the grant date, January 5, 2023. F2 · balance_after: Includes 29,336 deferred stock units. Read SEC document |
| January 05, 2023 Filed Feb 9, 2023 22:49 UTC Amendment | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008122 · doc4a.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,587 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vests in full on the earlier of (i) June 30, 2024 or (ii) the date that the Company holds its 2024 annual meeting of stockholders. F2 · shares: This amendment is being made to correct the vesting date and the number of Deferred Stock Units awarded to the reporting person on January 5, 2023. F3 · balance_after: Includes 29,638 deferred stock units. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:33 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 6,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035046 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,501 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vest in full on the first anniversary of the grant date, June 6, 2022. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:21 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stok | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042737 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,431 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:12 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantStock Option (right to buy) · Derivative | 24,701 | $0.00 Strike: $38.15 | $0.00 |
DisclosureSEC source: 0001209191-20-035668 · doc4.xml · derivative · entry 2 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24.701 Underlying: Common Stock · 24,701 shares Expires 2030-06-08 F2 · derivative.exercise_date: These stock options vest in 25% increments on the first, second, third and fourth anniversaries of the grant date, June 8, 2020. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:12 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 4,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035668 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,588 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 500 | $74.80 | $37,400.00 |
DisclosureSEC source: 0001209191-17-019697 · doc4.xml · nonDerivative · entry 4 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,961 F3 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F5 · price: Weighted average sales price from sales transactions ranging from $74.74 to $74.91. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | SaleCommon Stock | 24,340 | $74.21 | $1,806,271.40 |
DisclosureSEC source: 0001209191-17-019697 · doc4.xml · nonDerivative · entry 3 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,461 F3 · shares: Sales effected pursuant to a 10b5-1 Trading Plan adopted by the Reporting Person, which is intended to comply with Rule 10b5-1. F4 · price: Weighted average sales price from sales transactions ranging from $73.71 to $74.70. Upon request by the Commission staff or a security holder of the Issuer, either the Issuer or the Reporting Person will undertake to provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 97,375 | $0.00 Strike: $34.82 | $0.00 |
DisclosureSEC source: 0001209191-17-019697 · doc4.xml · derivative · entry 5 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,375 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing a right to purchase a total of 97,375 shares, was granted on January 2, 2009 and is fully vested. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 72,535 | $74.63 | $5,413,287.05 |
DisclosureSEC source: 0001209191-17-019697 · doc4.xml · nonDerivative · entry 2 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,801 F2 · shares: Payment of exercise price and tax liability by Issuer's withholding of shares incident to the respective option exercise. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 18:03 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 97,375 | $34.82 | $3,390,597.50 |
DisclosureSEC source: 0001209191-17-019697 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 17:48 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantPRSUs · Derivative | 13,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009679 · doc4.xml · derivative · entry 1 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,203 Underlying: Common Stock · 13,203 shares Expires not disclosed F1 · security: Each performance restricted stock unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. F2 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on March 1, 2016. On February 8, 2017, the Compensation Committee of the Issuer's Board of Directors certified that the PRSU award's performance condition had been satisfied. In accordance with the terms of the PRSU award, the award will vest in full on March 1, 2019. As the PRSU award did not constitute a derivative security, it was not required to be reported and was not reported on a Form 4 at the time of grant. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 2,660 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · derivative · entry 7 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 Underlying: Common Stock · 2,660 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F7 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, vested as to 2,660 shares on February 1, 2017, and will vest as to 2,660 shares on each of February 1, 2018 and February 1, 2019. F7 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on February 17, 2015. In accordance with the terms of the PRSU award, the award vested as to 2,661 shares on February 1, 2016, vested as to 2,660 shares on February 1, 2017, and will vest as to 2,660 shares on each of February 1, 2018 and February 1, 2019. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionPRSUs · Derivative | 12,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · derivative · entry 6 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each Performance Restricted Stock Unit ("PRSU") represents the right to receive one share of the Issuer's common stock upon vesting. F6 · derivative.exercise_date: This PRSU award was granted to the Reporting Person on February 19, 2014. In accordance with the terms of the PRSU award, the award vested as to 12,375 shares on February 1, 2016 and February 1, 2017. F6 · derivative.expiration_date: This PRSU award was granted to the Reporting Person on February 19, 2014. In accordance with the terms of the PRSU award, the award vested as to 12,375 shares on February 1, 2016 and February 1, 2017. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionRSUs · Derivative | 4,397 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · derivative · entry 5 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,397 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on February 19, 2014. In accordance with the terms of the RSU award, the award vested as to 4,397 shares on each of February 1, 2015, February 1, 2016 and February 1, 2017. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on February 19, 2014. In accordance with the terms of the RSU award, the award vested as to 4,397 shares on each of February 1, 2015, February 1, 2016 and February 1, 2017. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Tax withholdingCommon Stock | 9,856 | $70.76 | $697,410.56 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · nonDerivative · entry 4 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,961 F2 · shares: Shares withheld by the Issuer to satisfy tax withholding obligations. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 2,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · nonDerivative · entry 3 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 12,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · nonDerivative · entry 2 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 17:55 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionCommon Stock | 4,397 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-007780 · doc4.xml · nonDerivative · entry 1 Hannon Jason · CIK 0001330401 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Issuer equity awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.